Express Scripts (ESRX) 72.22 $ESRX Express Scripts

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Express Scripts (ESRX) 72.22 $ESRX

Express Scripts Holding Company to Present at an Upcoming Conference
PR Newswire - 2 hrs 29 mins ago
Express Scripts Holding Company (Nasdaq: ESRX) (the "Company" or "Express Scripts" announced today that it will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2016 at 1:00 p.m. Eastern Time (12:00 p.m. Central Time).
ESRX: 72.22 (-0.48)

Express Scripts' New Program to Lower Diabetes Care Costs
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:00AM CDT
Express Scripts Holding Company (ESRX) has launched the Diabetes Care Value Program to lower costs for patients and provide better care.
ESRX: 72.22 (-0.48), ANIP: 61.42 (+1.68), LLY: 77.23 (-0.52)

Express Scripts Launches Diabetes Care Value Programâ", Guaranteeing More Affordable, Higher-Quality Diabetes Care
PR Newswire - Tue Aug 30, 11:01PM CDT
Express Scripts (NASDAQ: ESRX) today announced the launch of its Diabetes Care Value Programâ", the industry's most comprehensive approach to improve pharmacy care while controlling plan costs for people with diabetes.
ESRX: 72.22 (-0.48)

Blog Coverage Walgreens Boots Alliance Partners with Prime Therapeutics for a Bigger Slice of the Prescription Drug Market
ACCESSWIRE - Tue Aug 30, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 30, 2016 / Active Wall St. blog coverage looks at the headline from Walgreens Boots Alliance, Inc. (NASDAQ: WBA) announced a strategic partnership with pharmacy benefit manager (PBM) Prime Therapeutics on August 29, 2016 to form a new retail pharmacy network that combines mail order and speciality pharma business. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
ESRX: 72.22 (-0.48), WBA: 81.54 (+0.83), UNH: 135.74 (-0.31), RAD: 7.54 (+0.01)


Mylan launching cheaper, generic version of EpiPen
By LINDA A. JOHNSON and TOM MURPHY - AP - Mon Aug 29, 4:20PM CDT
The maker of EpiPens will start selling a cheaper, generic version of the emergency allergy shots as the furor over repeated U.S. price hikes continues — and looming competition threatens its near-monopoly.
ESRX: 72.22 (-0.48), MYL: 41.92 (-0.44)

Stock Market News for August 26, 2016
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 9:09AM CDT
Benchmarks finished in the red on Thursday as investors refrained from making big bets ahead of Fed Chief Janet Yellen’s speech at Jackson Hole, Wyoming today
MNK: 75.59 (+1.05), TSLA: 200.77 (-11.24), ENDP: 20.23 (-0.47), F: 12.44 (-0.16), MDT: 86.98 (-0.05), GME: 28.03 (-0.36), MYL: 41.92 (-0.44), PDCO: 46.03 (+0.03), TIF: 70.37 (-1.00), BA: 129.90 (+0.45), ESRX: 72.22 (-0.48), STJ: 78.14 (+0.22), SSYS: 21.33 (-0.01), TECD: 73.34 (-0.90), ADSK: 67.37 (-0.03)


Mylan boosts EpiPen patient programs, doesn't budge on price
By LINDA A. JOHNSON and TOM MURPHY - AP - Thu Aug 25, 4:45PM CDT
The maker of EpiPens offered patients more help to pay for its costly emergency allergy shots but didn't budge Thursday on the $608 price.
ESRX: 72.22 (-0.48), VRX: 29.12 (+0.09), MYL: 41.92 (-0.44), VRX.TO: 38.09 (unch)

Look for Shares of Express Scripts to Potentially Rebound after Yesterday's 4.00% Sell Off
Comtex SmarTrend(R) - Thu Aug 25, 11:59AM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $73.01 to a high of $76.08. Yesterday, the shares fell 4.0%, which took the trading range below the 3-day low of $76.00 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ESRX: 72.22 (-0.48)

SmarTrend Watching for Potential Rebound in Shares of Express Scripts After 4.00% Loss
Comtex SmarTrend(R) - Thu Aug 25, 11:57AM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $73.01 to a high of $76.08. Yesterday, the shares fell 4.0%, which took the trading range below the 3-day low of $76.00 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ESRX: 72.22 (-0.48)

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Express Scripts Holding Company for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Thu Aug 25, 11:51AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Express Scripts Holding Company (NASDAQ: ESRX).
ANTM: 123.36 (-1.72), ESRX: 72.22 (-0.48)

PharmCo to Offer Emergency Prescriptions to Residents in Louisiana Flood Zone
Marketwired - Thu Aug 25, 9:10AM CDT
MIAMI, FL--(Marketwired - August 25, 2016) - Progressive Care Inc. (OTC PINK: RXMD), through its subsidiary Pharmco LLC, a South Florida health services organization and provider of prescription pharmaceuticals specializing in health practice risk management, compounded medications, the sale of anti-retroviral medications and related medication therapy management, and the supply of prescription medications to long term care facilities, has begun offering emergency prescription services to Louisiana Flood Zone residents.
ESRX: 72.22 (-0.48)

Express Scripts (ESRX) Breaks Through Support at $76.38
Comtex SmarTrend(R) - Fri Aug 19, 8:39AM CDT
Shares of Express Scripts (NASDAQ:ESRX) opened today below their pivot of $76.77 and have already reached the first level of support at $76.38. Should the shares continue to fall, the support pivots of $76.15 and $75.53 will be of interest.
ESRX: 72.22 (-0.48)

Watch for Express Scripts to Potentially Pullback After Gaining 1.20% Yesterday
Comtex SmarTrend(R) - Mon Aug 15, 2:48PM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $76.25 to a high of $77.14. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $76.65 on volume of 875,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ESRX: 72.22 (-0.48)

Express Scripts Set to Possibly Pullback After Yesterday's Rally of 1.08%
Comtex SmarTrend(R) - Fri Aug 05, 1:48PM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $75.73 to a high of $76.75. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $76.41 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ESRX: 72.22 (-0.48)

Express Scripts Announces Final Results of Maximum Tender Offers
PR Newswire - Thu Jul 28, 8:15AM CDT
Express Scripts Holding Company (NASDAQ: ESRX) (the "Company" or "Express Scripts" today announced the final tender results for its previously announced tender offers (the "Maximum Tender Offers" to purchase for cash up to an aggregate principal amount of the debt securities listed in the table below (collectively, the "Notes" and each a "series" that will not result in an aggregate amount that all holders of any such series of Notes are entitled to receive, excluding accrued and unpaid interest, for their Notes of such series that are validly tendered and accepted for purchase in the Maximum Tender Offers exceeding the applicable Aggregate Maximum Tender Amount set forth in the table below. The Maximum Tender Offers were made pursuant to the terms and conditions set forth in the offer to purchase, dated June 29, 2016, as amended by the Company's press releases dated July 14, 2016 announcing the pricing and the early tender results of the Maximum Tender Offers, and the related letter of transmittal (as they may each be amended or supplemented from time to time, the "Tender Offer Documents" . The Company refers investors to the Tender Offer Documents for the complete terms and conditions of the Maximum Tender Offers.
ESRX: 72.22 (-0.48)

Top 7 Research Reports for July 27, 2016
Sheraz Mian - Zacks Investment Research - Wed Jul 27, 1:01PM CDT
Top 7 Research Reports for July 27, 2016
RAI: 49.75 (+0.18), SWK: 123.57 (-0.18), ESRX: 72.22 (-0.48), HON: 116.13 (-0.58), CHK: 6.25 (-0.10), TXN: 69.70 (+0.16), VFC: 61.56 (-0.49)

Express Scripts (ESRX) Posts In-Line Earnings, Lags Revenues (Revised)
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 10:19AM CDT
Pharmacy benefit manager Express Scripts Holding Company (ESRX) posted second-quarter 2016 earnings per share (excluding special items) of $1.57, in line with the Zacks Consensus Estimate.
ANTM: 123.36 (-1.72), JNJ: 119.08 (-0.26), ESRX: 72.22 (-0.48), GILD: 77.42 (-0.96)

DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit Against Express Scripts Holding Company and Reminds Investors with Losses to Contact the Firm
ACCESSWIRE - Thu Jun 23, 10:41PM CDT
LOS ANGELES, CA / ACCESSWIRE / June 23, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Express Scripts Holding Company ("Express Scripts" or the "Company" (NASDAQ: ESRX) concerning possible violations of federal securities laws between February 24, 2015 and March 21, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 5, 2016, lead plaintiff motion deadline.
ESRX: 72.22 (-0.48)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 342

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 178

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 13

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 34

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 175

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading

Top 5 Most Recently Viewed Articles

Orion Corporation's Manager Transactions Highlight Executive Moves

Updated Category News Views 133

Understanding Orion Corporation's Executive Transactions Orion Corporation, a prominent player in the global pharmaceutical industry, has recently disclosed significant transactions involving its management, shedding light on financial movements that reflect company growth and strategy. Key Details on Managerial Transactions Recently, Orion Corporation reported under the...

Continue Reading
Congressman Questions SEC's 'Digital Asset Security' Definition

Updated Category News Views 150

Congressman Ritchie Torres Questions SEC's Use of Terminology Representative Ritchie Torres, a Democratic representative from New York, has recently shared his concerns about the phrase "digital asset security" as used by the U.S. Securities and Exchange Commission (SEC). He’s particularly interested in the legal basis and origins of this term. Congressional Dialogue...

Continue Reading
Investigating Claims for StubHub Investors: Your Options

Updated Category News Views 173

Investigation of Claims on Behalf of StubHub Investors Faruqi & Faruqi, LLP, a prominent name in national securities law, is currently looking into potential claims related to StubHub Holdings, Inc. (NYSE: STUB). This initiative aims to assist investors who might have faced losses due to the misleading statements made about the company's financial performance during its...

Continue Reading
Sarepta Therapeutics Faces Class Action Amid Safety Concerns

Updated Category News Views 256

Introduction to Sarepta Therapeutics Sarepta Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, particularly those associated with genetic factors. The company is well-known for its gene therapy treatments and aims to revolutionize treatment options for patients with Duchenne muscular dystrophy and similar...

Continue Reading